IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, small molecule drug discovery, translational biology and clinical development.
”IDEAYA was founded with the premise that attracting the industry's best scientists and focusing on areas of transformative research is a proven model for delivering game-changing medicines to patients. Our people are passionate and proven cancer biologists, translational biologists, drug discovery chemists and development professionals. As an organization, we believe that our entrepreneurial spirit and nimbleness, and commitment to foster innovation, teamwork and excellence is what sets us apart. Our greatest asset is our scientists and their passion to discover innovative new therapies for cancer patients.Yujiro S. HataIDEAYA Chief Executive Officer
We are pursuing an integrated approach for biomarker and small molecule drug discovery and development to broadly address unmet needs in cancer. Our capabilities include target and biomarker discovery integrated with small molecule therapeutics, from early discovery through clinical development. IDEAYA is employing a translational platform based on cutting-edge technologies for discovery, validation and clinical development of biomarkers in parallel with novel therapeutics.
Biomarker-enabled translational approaches help enhance patient outcomes – by identifying patients likely to respond to particular therapies and by providing clinical insights based on extent of target modulation.